VCYT · Veracyte, Inc.
$41.11
-2.19% last session
End-of-day data · close of 2026-09-11
Market cap
$3B
Enterprise value
$3B
Trailing P/E
31.4
Forward P/E
21.6
Dividend yield
—
Beta
1.93
Avg volume
1M
Employees
1K
Daily Change %
-2.19%
5 Days Change
3.13%
10 Days Change
1.55%
30 Days Change
-5.49%
60 Days Change
-23.01%
Month to Day Change
0.99%
Year to Day Change
4.18%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — VCYT
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-09
Latest call per bank · past 12 months
UBS
Buy$65.00
+54.7% vs priceMorgan Stanley
Underweight$44.00
+4.7% vs priceJefferies
Buy$45.00
+7.1% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-09 | UBS | Maintains | Buy | $52.00 → $65.00 |
| 2026-08-04 | Piper Sandler | Maintains | Overweight | $66.00 → $54.00 |
| 2026-08-04 | Stephens & Co. | Maintains | Overweight | $68.00 → $55.00 |
| 2026-08-04 | Morgan Stanley | Maintains | Underweight | $47.00 → $44.00 |
| 2026-08-03 | Canaccord Genuity | Maintains | Hold | $60.00 → $50.00 |
| 2026-07-31 | Needham | Maintains | Buy | $57.00 → $69.00 |
| 2026-07-30 | Needham | Maintains | Buy | $57.00 → $69.00 |
| 2026-07-15 | Piper Sandler | Initiates | Overweight | $0.00 → $66.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 38 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 16.6% below the 50-day MA ($49.31).
- Price vs 200-day MA: Trading 3.7% below the 200-day MA ($42.68).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is positive (+0.21) — short-term momentum is improving.
- 52-week range: Price sits between the 52-week low ($30.01) and high ($60.49).
VCYT Price Chart
Loading chart for VCYT…
Fundamentals
About Veracyte, Inc.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
More in Diagnostics & Research
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.